The six-month off-treatment follow-up period of the ARCHER Phase 2 trial has been completed and Annexon plans to report the final results from the study at the American Academy of Ophthalmology 2023 Annual Meeting to be held November 3-6, 2023, in San Francisco, Calif.
About Geographic Atrophy
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD), an eye disease that is the
leading cause of blindness in the elderly. GA is a chronic progressive neurodegenerative disorder of the retina involving the loss of photoreceptor synapses and cells in the outer retina. GA affects an estimated one million people in the United
States and five million people globally, severely limiting their independence and causing frustration, anxiety and emotional hardship. Effective treatments that preserve vision are still needed, as no currently approved therapies have been shown in
clinical trials to significantly prevent vision loss.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory
aspects of classical complement pathway activation before it starts. As the only company solely focused on shutting down C1q, Annexon is developing a fit-for-purpose
pipeline of therapeutics designed to provide meaningful benefits across multiple diseases of the body, brain and eye. With proof-of concept data in both Guillain-Barré syndrome and geographic atrophy,
Annexon is rigorously advancing its mid-to late-stage clinical trials to bring their potential treatments to patients as quickly as possible. To learn more visit annexonbio.com.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by
terminology such as aim, anticipate, assume, believe, contemplate, continue, could, design, due, estimate, expect,
goal, intend, may, objective, plan, positioned, potential, predict, seek, should, suggest, target,
on track, will, would and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than
statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: ability of ANX007 to preserve vision and protect photoreceptor damage;
the plans to further a global pivotal Phase 3 program in ANX007; the potential benefit of ANX007, if approved, compared to existing therapies; the potential ability to reach patients faster with the PRIME designation; market size;; the potential
benefits from treatment with anti-C1q therapy; and continuing advancement of the companys portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the companys history of net operating losses; the companys ability
to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the companys product candidates; the effects of public health crises on the companys clinical programs and business operations; the
companys ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the companys product candidates; the companys reliance on third-party
suppliers and manufacturers; the outcomes of any future collaboration agreements; and the companys ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail
under the section titled Risk Factors contained in the companys Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the companys
other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release.
Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com